Download Files:
Merestinib
$132 – $768
Products Details
Product Description
– Merestinib (LY2801653) is a potent, orally bioavailable c-Met inhibitor (Ki=2 nM) with anti-tumor activities. Merestinib (LY2801653) also has potent activity against MST1R (IC50=11 nM), FLT3 (IC50=7 nM), AXL (IC50=2 nM), MERTK (IC50=10 nM), TEK (IC50=63 nM), ROS1, DDR1/2 (IC50=0.1/7 nM) and MKNK1/2 (IC50=7 nM)[1][2].
Web ID
– HY-15514
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C30H22F2N6O3
Citations
– Cancer Discov. 2016 Dec;6(12):1334-1341.|Clin Cancer Res. 2020 Jun 1;26(11):2615-2625.|Patent. WO2017019702A1.|Methods Mol Biol. 2018;1711:351-398.
References
– [1]Barat S, et al. Targeting c-MET by LY2801653 for treatment of cholangiocarcinoma. Mol Carcinog. 2016 Jan 12.|[2]Yan SB, et al. LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models. Invest New Drugs. 2013 Aug;31(4):833-44.
CAS Number
– 1206799-15-6
Molecular Weight
– 552.53
Compound Purity
– 99.99
SMILES
– O=C(C1=CC=C(C)N(C2=CC=C(F)C=C2)C1=O)NC3=CC=C(OC4=CC5=C(N(C)N=C5)C=C4C6=CNN=C6)C(F)=C3
Clinical Information
– Phase 2
Research Area
– Cancer
Solubility
– DMSO : ≥ 32 mg/mL
Target
– c-Met/HGFR;Discoidin Domain Receptor;FLT3;ROS Kinase
Pathway
– Protein Tyrosine Kinase/RTK
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
